BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/20/2025 8:41:22 AM | Browse: 59 | Download: 124
 |
Received |
|
2025-03-30 11:43 |
|
Peer-Review Started |
|
2025-03-30 11:43 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-23 11:49 |
|
Revised |
|
2025-05-03 08:06 |
|
Second Decision |
|
2025-06-26 02:38 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-26 07:19 |
|
Articles in Press |
|
2025-06-26 07:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-08-07 02:35 |
|
Publish the Manuscript Online |
|
2025-08-20 08:41 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Recent progress in the use of periplocin, periplocymarin and periplogenin in cancer treatment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xin Sun, Xiao-Wei Shi, Lei Han, Yi-Fan Zhang, Yang Xu and Yu-Cheng Lu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Traditional Chinese Medicine Science and Technology Project of Shandong Province, China |
No. M-2023131 |
| The Science and Technology Development Fund Project of the Affiliated Hospital of Xuzhou Medical University, China |
No. XYFM202348 |
|
| Corresponding Author |
Yu-Cheng Lu, PhD, Senior Researcher, Department of Biobank, Linyi People's Hospital, No. 27 Jiefang Road, District Lanshan, Linyi 276000, Shandong Province, China. luyu-20@163.com |
| Key Words |
Periplocin; Periplocymarin; Periplogenin; Cancer therapy; Cortex Periplocae |
| Core Tip |
Periplocin, periplocymarin and periplogenin are three cardiac glycosides widely recognized as the main active ingredients of Cortex Periplocae. Various experiments have shown that they exert antitumor effects by regulating cell cycle proteins, blocking malignant cell proliferation, activating caspase proteases and inducing apoptosis in cancer cells. This minireview focuses on the tumor inhibitory effects of periplocin, periplocymarin and periplogenin. |
| Publish Date |
2025-08-20 08:41 |
| Citation |
<p>Sun X, Shi XW, Han L, Zhang YF, Xu Y, Lu YC. Recent progress in the use of periplocin, periplocymarin and periplogenin in cancer treatment. <i>World J Clin Oncol</i> 2025; 16(8): 107490</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i8/107490.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i8.107490 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
